Product Code: GVR-2-68038-851-0
Neurovascular Devices Market Growth & Trends:
The global neurovascular devices market size is expected to reach USD 4.53 billion by 2030, registering a CAGR of 6.01% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of neurological illnesses such as stroke, brain aneurysm, and cerebral artery stenosis is driving growth of the neurovascular devices market. According to the World Stroke Organization (WSO), in 2022, there will be more than 12.2 million new strokes per year.
One in every four adults above the age of 25 will suffer a stroke throughout their lifetime. In addition, nearly 7.6 million new ischemic strokes occur each year. Around 62.0% of all incident strokes worldwide are ischemic strokes, with more than 1.2 million new subarachnoid hemorrhages occurring each year. As a result, the figures show that there is a significant demand for the neurovascular devices, which is driving neurovascular device market expansion.
The rising prevalence of brain aneurysms in both developed and developing countries is driving the introduction of technologically advanced products to the market. Some significant therapeutic techniques for an intracranial aneurysm include surgical clipping, endovascular coiling, and flow diverters. Market participants are constantly working to introduce technologically advanced products to the market.
For instance, in September 2021, Medtronic plc. announced the CE Mark clearance of its radial artery access portfolio, which comprises the Rist 079 Access Radial Guide Catheter and the Access Rist Radial Selective Catheter. Furthermore, in March 2022, Micro Port Scientific Company announced that its Hyper flex Balloon Catheter has received registration approval from the Japan Pharmaceuticals and Medical Devices Agency (PMDA).
Reduced postoperative discomfort and faster recovery are the factors expanding use of the minimally invasive operations and fueling R&D in this field. Endovascular coiling is a minimally invasive surgery that is frequently suggested by the clinicians for the treatment of cerebral aneurysms. Hydro Coils (MicroVention, Tustin, California, USA) have permitted the treatment of more complex aneurysmal structures with reduced recurrence rates as compared to bare-platinum coils. As a result, increased demand for the minimally invasive procedures is supporting neurovascular device market expansion.
Neurovascular Devices Market Report Highlights:
- Cerebral embolization and aneurysm coiling devices held the largest market share of around 36.02% in 2024. Coil embolization is a minimally invasive procedure for the treatment of aneurysms, wherein, the material closes the sac and reduces the risk of bleeding.
- Stroke held the largest market share of around 56.86% in 2024, owing to the factors such as increasing prevalence of hypertension, stroke, and other neurological disorders.
- 0.021" held the largest market share of around 27.08% in 2024. Segment growth can be attributed to various advantages provided by the 0.021" devices, along with various product launches and product approvals.
- Hospitals held the largest market share of around 70.79% in 2024. The growth of this segment can be attributed primarily to the increasing patient pool suffering from neurovascular disorders, such as ischemic & hemorrhagic stroke, brain aneurysm, Traumatic brain injury (TBI), and Arteriovenous Malformation (AVM).
- North America neurovascular devices dominated the market with a share of 27.62% in 2024 owing to the presence of key manufacturers such as Penumbra, Inc., Stryker Corporation, Johnson & Johnson, and Merit medical systems, Inc. in the region.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
- 1.2.1. Device
- 1.2.2. Therapeutic Applications
- 1.2.3. Size
- 1.2.4. End Use
- 1.2.5. Regional Scope
- 1.2.6. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Regional outlook
- 2.4. Competitive Insights
Chapter 3. Neurovascular Devices Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing Prevalence of Neurovascular Diseases
- 3.2.1.2. Technological Advancements In Neurovascular Devices
- 3.2.1.3. Rising Number of Awareness Initiatives
- 3.2.1.4. Increasing Demand For Minimally Invasive Procedures
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Product Recalls
- 3.2.2.2. High Treatment Cost Associated With Neurovascular Disorders
- 3.3. Neurovascular Devices Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Technological landscape
- 3.3.2.5. Environmental landscape
- 3.3.2.6. Legal landscape
Chapter 4. Neurovascular Devices Market: Segment Analysis, By Device, 2018 - 2030 (USD Million and Volume Unit)
- 4.1. Definition and Scope
- 4.2. Device Market Share Analysis, 2024 & 2030
- 4.3. Global Neurovascular Devices Market, by Device, 2018 to 2030
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 4.4.1. Cerebral Embolization and Aneurysm coiling devices
- 4.4.1.1. Cerebral embolization and aneurysm coiling devices market, 2018 - 2030 (USD Million and Volume Unit)
- 4.4.1.2. Embolic coils
- 4.4.1.2.1. Embolic coils market, 2018 - 2030 (USD Million)
- 4.4.1.3. Flow diverters
- 4.4.1.3.1. Flow diverters market, 2018 - 2030 (USD Million)
- 4.4.1.4. Liquid embolic agents
- 4.4.1.4.1. Liquid embolic agents market, 2018 - 2030 (USD Million)
- 4.4.2. Cerebral angioplasty and stenting sytems
- 4.4.2.1. Cerebral angioplasty and stenting sytems market, 2018 - 2030 (USD Million and Volume Unit)
- 4.4.2.2. Carotid Artery Stents
- 4.4.2.2.1. Carotid artery stents market, 2018 - 2030 (USD Million)
- 4.4.2.3. Embolic Protection Devices
- 4.4.2.3.1. Embolic protection systems devices market, 2018 - 2030 (USD Million)
- 4.4.3. Neurothrombectomy devices
- 4.4.3.1. Neurothrombectomy devices market, 2018 - 2030 (USD Million and Volume Unit)
- 4.4.3.2. Clot Retrieval Devices
- 4.4.3.2.1. Clot retrieval devices market, 2018 - 2030 (USD Million)
- 4.4.3.3. Suction Devices
- 4.4.3.3.1. Suction devices market, 2018 - 2030 (USD Million)
- 4.4.3.4. Vascular Snares
- 4.4.3.4.1. Vascular snares market, 2018 - 2030 (USD Million)
- 4.4.4. Support devices
- 4.4.4.1. Support devices market, 2018 - 2030 (USD Million and Volume Unit)
- 4.4.4.2. Micro Catheters
- 4.4.4.2.1. Micro catheters market, 2018 - 2030 (USD Million)
- 4.4.4.3. Micro Guidewires
- 4.4.4.3.1. Micro guidewires market, 2018 - 2030 (USD Million)
- 4.4.5. Trans Radial Access Devices
- 4.4.5.1. Trans radial access devices market, 2018 - 2030 (USD Million and Volume Unit)
Chapter 5. Neurovascular Devices Market: Segment Analysis, By Therapeutic Applications, 2018 - 2030 (USD Million)
- 5.1. Definition and Scope
- 5.2. Therapeutic Applications Market Share Analysis, 2024 & 2030
- 5.3. Global Neurovascular Devices Market, by Therapeutic Applications, 2018 to 2030
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 5.4.1. Stroke
- 5.4.1.1. Stroke market, 2018 - 2030 (USD Million)
- 5.4.2. Cerebral artery stenosis
- 5.4.2.1. Cerebral artery stenosis market, 2018 - 2030 (USD Million)
- 5.4.3. Cerebral aneurysm
- 5.4.3.1. Cerebral aneurysm market, 2018 - 2030 (USD Million)
- 5.4.3.2. Aneurysmal Subarachnoid Hemorrhage
- 5.4.3.2.1. Aneurysmal subarachnoid hemorrhage market, 2018 - 2030 (USD Million)
- 5.4.3.3. Others
- 5.4.3.3.1. Others market, 2018 - 2030 (USD Million)
- 5.4.4. Others
- 5.4.4.1. Others market, 2018 - 2030 (USD Million)
Chapter 6. Neurovascular Devices Market: Segment Analysis, By Size, 2018 - 2030 (USD Million)
- 6.1. Definition and Scope
- 6.2. Size Market Share Analysis, 2024 & 2030
- 6.3. Global Neurovascular Devices Market, by Size, 2018 to 2030
- 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 6.4.1. 0.027"
- 6.4.1.1. 0.027" market, 2018 - 2030 (USD Million)
- 6.4.2. 0.021"
- 6.4.2.1. 0.021" market, 2018 - 2030 (USD Million)
- 6.4.3. 0.071"
- 6.4.3.1. 0.071" market, 2018 - 2030 (USD Million)
- 6.4.4. 0.017"
- 6.4.4.1. 0.017" market, 2018 - 2030 (USD Million)
- 6.4.5. 0.019"
- 6.4.5.1. 0.019" market, 2018 - 2030 (USD Million)
- 6.4.6. 0.013"
- 6.4.6.1. 0.013" market, 2018 - 2030 (USD Million)
- 6.4.7. 0.058"
- 6.4.7.1. 0.058" market, 2018 - 2030 (USD Million)
- 6.4.8. 0.068"
- 6.4.8.1. 0.068" market, 2018 - 2030 (USD Million)
- 6.4.9. Others
- 6.4.9.1. Others market, 2018 - 2030 (USD Million)
Chapter 7. Neurovascular Devices Market: Segment Analysis, By End Use, 2018 - 2030 (USD Million)
- 7.1. Definition and Scope
- 7.2. End Use Market Share Analysis, 2024 & 2030
- 7.3. Global Neurovascular Devices Market, by End Use, 2018 to 2030
- 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 7.4.1. Hospital
- 7.4.1.1. Hospital market, 2018 - 2030 (USD Million)
- 7.4.2. Specialty clinics
- 7.4.2.1. Specialty clinics market, 2018 - 2030 (USD Million)
- 7.4.3. Others
- 7.4.3.1. Others market, 2018 - 2030 (USD Million)
Chapter 8. Neurovascular Devices Market: Regional Estimates & Trend Analysis
- 8.1. Regional Dashboard
- 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 8.3. North America
- 8.3.1. U.S.
- 8.3.1.1. Key country dynamics
- 8.3.1.2. Regulatory framework/ reimbursement structure
- 8.3.1.3. Competitive scenario
- 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 8.3.2. Canada
- 8.3.2.1. Key country dynamics
- 8.3.2.2. Regulatory framework/ reimbursement structure
- 8.3.2.3. Competitive scenario
- 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4. Europe
- 8.4.1. UK
- 8.4.1.1. Key country dynamics
- 8.4.1.2. Regulatory framework/ reimbursement structure
- 8.4.1.3. Competitive scenario
- 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.2. Germany
- 8.4.2.1. Key country dynamics
- 8.4.2.2. Regulatory framework/ reimbursement structure
- 8.4.2.3. Competitive scenario
- 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.3. France
- 8.4.3.1. Key country dynamics
- 8.4.3.2. Regulatory framework/ reimbursement structure
- 8.4.3.3. Competitive scenario
- 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.4. Italy
- 8.4.4.1. Key country dynamics
- 8.4.4.2. Regulatory framework/ reimbursement structure
- 8.4.4.3. Competitive scenario
- 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.5. Spain
- 8.4.5.1. Key country dynamics
- 8.4.5.2. Regulatory framework/ reimbursement structure
- 8.4.5.3. Competitive scenario
- 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.6. Norway
- 8.4.6.1. Key country dynamics
- 8.4.6.2. Regulatory framework/ reimbursement structure
- 8.4.6.3. Competitive scenario
- 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.7. Sweden
- 8.4.7.1. Key country dynamics
- 8.4.7.2. Regulatory framework/ reimbursement structure
- 8.4.7.3. Competitive scenario
- 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.8. Denmark
- 8.4.8.1. Key country dynamics
- 8.4.8.2. Regulatory framework/ reimbursement structure
- 8.4.8.3. Competitive scenario
- 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5. Asia Pacific
- 8.5.1. Japan
- 8.5.1.1. Key country dynamics
- 8.5.1.2. Regulatory framework/ reimbursement structure
- 8.5.1.3. Competitive scenario
- 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.2. China
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Regulatory framework/ reimbursement structure
- 8.5.2.3. Competitive scenario
- 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.3. India
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Regulatory framework/ reimbursement structure
- 8.5.3.3. Competitive scenario
- 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.4. Australia
- 8.5.4.1. Key country dynamics
- 8.5.4.2. Regulatory framework/ reimbursement structure
- 8.5.4.3. Competitive scenario
- 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.5. South Korea
- 8.5.5.1. Key country dynamics
- 8.5.5.2. Regulatory framework/ reimbursement structure
- 8.5.5.3. Competitive scenario
- 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.6. Thailand
- 8.5.6.1. Key country dynamics
- 8.5.6.2. Regulatory framework/ reimbursement structure
- 8.5.6.3. Competitive scenario
- 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6. Latin America
- 8.6.1. Brazil
- 8.6.1.1. Key country dynamics
- 8.6.1.2. Regulatory framework/ reimbursement structure
- 8.6.1.3. Competitive scenario
- 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.2. Argentina
- 8.6.2.1. Key country dynamics
- 8.6.2.2. Regulatory framework/ reimbursement structure
- 8.6.2.3. Competitive scenario
- 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.3. Mexico
- 8.6.3.1. Key country dynamics
- 8.6.3.2. Regulatory framework/ reimbursement structure
- 8.6.3.3. Competitive scenario
- 8.6.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7. MEA
- 8.7.1. South Africa
- 8.7.1.1. Key country dynamics
- 8.7.1.2. Regulatory framework/ reimbursement structure
- 8.7.1.3. Competitive scenario
- 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.2. Saudi Arabia
- 8.7.2.1. Key country dynamics
- 8.7.2.2. Regulatory framework/ reimbursement structure
- 8.7.2.3. Competitive scenario
- 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.3. UAE
- 8.7.3.1. Key country dynamics
- 8.7.3.2. Regulatory framework/ reimbursement structure
- 8.7.3.3. Competitive scenario
- 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.4. Kuwait
- 8.7.4.1. Key country dynamics
- 8.7.4.2. Regulatory framework/ reimbursement structure
- 8.7.4.3. Competitive scenario
- 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Market Participant Categorization
- 9.2. Recent Developments & Impact Analysis by Key Market Participants
- 9.3. Company Market Share Analysis, 2024
- 9.4. Key Company Profiles
- 9.4.1. Medtronic
- 9.4.1.1. Company overview
- 9.4.1.2. Financial performance
- 9.4.1.3. Product benchmarking
- 9.4.1.4. Strategic initiatives
- 9.4.2. Stryker Corporation
- 9.4.2.1. Company overview
- 9.4.2.2. Financial performance
- 9.4.2.3. Product benchmarking
- 9.4.2.4. Strategic initiatives
- 9.4.3. Terumo Corporation
- 9.4.3.1. Company overview
- 9.4.3.2. Financial performance
- 9.4.3.3. Product benchmarking
- 9.4.3.4. Strategic initiatives
- 9.4.4. Penumbra, Inc.
- 9.4.4.1. Company overview
- 9.4.4.2. Financial performance
- 9.4.4.3. Product benchmarking
- 9.4.4.4. Strategic initiatives
- 9.4.5. Johnson & Johnson Services, Inc.
- 9.4.5.1. Company overview
- 9.4.5.2. Financial performance
- 9.4.5.3. Product benchmarking
- 9.4.5.4. Strategic initiatives
- 9.4.6. Integra LifeSciences Corporation
- 9.4.6.1. Company overview
- 9.4.6.2. Financial performance
- 9.4.6.3. Product benchmarking
- 9.4.6.4. Strategic initiatives
- 9.4.7. Acandis GmbH
- 9.4.7.1. Company overview
- 9.4.7.2. Financial performance
- 9.4.7.3. Product benchmarking
- 9.4.7.4. Strategic initiatives
- 9.4.8. Spiegelberg GmbH & Co. KG
- 9.4.8.1. Company overview
- 9.4.8.2. Financial performance
- 9.4.8.3. Product benchmarking
- 9.4.8.4. Strategic initiatives
- 9.4.9. MicroPort Scientific Corporation
- 9.4.9.1. Company overview
- 9.4.9.2. Financial performance
- 9.4.9.3. Product benchmarking
- 9.4.9.4. Strategic initiatives
- 9.4.10. ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
- 9.4.10.1. Company overview
- 9.4.10.2. Financial performance
- 9.4.10.3. Product benchmarking
- 9.4.10.4. Strategic initiatives